Form 4: KKR Sells 5.8 Million Shares of BridgeBio Pharma (BBIO) in Block Trade
SEC Form 4
KKR Genetic Disorder L.P. sold 5.8 million shares of BridgeBio Pharma at $25.75 per share on September 13, 2024.
Summary
- KKR Genetic Disorder L.P. sold 5,800,000 shares of BridgeBio Pharma, Inc. (BBIO) common stock on September 13, 2024.
- The sale price was $25.75 per share.
- The transaction was executed as a block sale pursuant to Rule 144 of the Securities Act of 1933.
- Following the sale, KKR Genetic Disorder L.P. indirectly holds 25,260,971 shares of BridgeBio Pharma.
- Multiple entities and individuals related to KKR, including KKR Genetic Disorder GP LLC, KKR Group Partnership L.P., KKR Group Holdings Corp., KKR Group Co. Inc., KKR & Co. Inc., KKR Management LLP, Henry R. Kravis, and George R. Roberts, are listed as reporting persons.
- These reporting persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest.
Sentiment
Score: 5
Explanation: The sentiment is neutral. It's a standard Form 4 filing indicating a sale of shares. The impact on the stock price will depend on market interpretation.
Industry Context
This sale by KKR, a major shareholder, could be interpreted in various ways by the market. It could be a strategic portfolio adjustment by KKR, or it could reflect their view on the future prospects of BridgeBio Pharma. The market will likely analyze the reasons behind this sale and its potential impact on BBIO's stock price.
Comparison to Industry Standards
- Block trades by major shareholders are common in the biopharmaceutical industry.
- Similar transactions can be seen with other major investment firms holding significant stakes in publicly traded biotech companies.
- The impact on the stock price often depends on the size of the sale relative to the company's market capitalization and the overall market sentiment.
Stakeholder Impact
- Shareholders may react to the news of KKR's sale, potentially impacting the stock price.
- The sale could influence investor confidence in BridgeBio Pharma.
Key Dates
| Date | Description |
|---|---|
| 09/13/2024 | Date of the transaction: sale of 5,800,000 shares of BBIO common stock. |
| 09/17/2024 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.